Edward M. Rudnic

Oral insulin delivery

An oral form of insulin has been the elusive goal for many investigators since the proteins initial discovery by Banting and Best in 1922. This paper will attempt to answer why this is the case by describing the substantial barriers to the development of oral insulin formulations. Following this description, specific strategies to overcome the barriers to oral insulin administration will be discussed. Most notably, the use of permeation enhancers, protease inhibitors, enteric coatings and polymer microsphere formulations will be covered, including commentary on which methods hold more promise towards the successful development of oral insulin.

Pharmacokinetic Evaluation of Twice-Daily Extended-Release Carbamazepine (CBZ) and Four-Times-Daily Immediate-Release CBZ in Patients with Epilepsy

Summary: Purpose: A new capsule dosage form of carbamazepine (CBZ) has been developed, consisting of three different types of beads (immediate‐release, extended‐release, and enteric‐release) that may be taken sprinkled on food or swallowed for easy administration. We compared the pharmacokinetics of the extended‐release dosage form of CBZ (Carbatrol capsules) twice daily with the conventional immediate‐release formulation of CBZ four times daily.

The influence of plasma butyrylcholinesterase concentration on the in vitro hydrolysis of cocaine in human plasma

In humans, the plasma enzyme butyrylcholinesterase, BChE (EC 3.1.1.8), mediates the in vivo plasma hydrolysis of cocaine to the pharmacologically inactive metabolite ecgonine methyl ester, EME. This enzyme has been purified from human plasma to investigate the potential as a treatment for cocaine intoxication.